|
Press Releases |
|
|
|
Monday, March 14, 2022 |
|
Jacobson Pharma's Chairman Uplifts Shareholding to Above 60% |
Mr. Derek Sum, Chairman and Chief Executive Officer of Jacobson Pharma Corporation Limited (the "Company"; together with its subsidiaries, the "Group"; Stock Code: 2633), a leading company engaged in the research more info >> |
|
Friday, November 26, 2021 |
|
雅各臣公布二零二二财年中期业绩 |
从事基础药物、专科药物及品牌医疗保健产品研发、生产、市场推广及销售的领先企业─雅各臣科研制药有限公司(「雅各臣」或「公司」;股份代号:2633 )今天公布公司及其附属公司(统称「集团」)截至二零二一年九月三十日止六个月(「报告期」)的中期业绩。 more info >> |
|
雅各臣公佈二零二二財年中期業績 |
從事基礎藥物、專科藥物及品牌醫療保健產品研發、生產、市場推廣及銷售的領先企業─雅各臣科研製藥有限公司(「雅各臣」或「公司」;股份代號:2633 )今天公佈公司及其附屬公司(統稱「集團」)截至二零二一年九月三十日止六個月(「報告期」)的中期業績。 more info >> |
|
Jacobson Pharma Announces FY2022 Interim Results |
Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaging in the research, development, production, marketing and sale of essential medicines more info >> |
|
Tuesday, June 29, 2021 |
|
雅各臣公布二零二一财年全年业绩 |
从事基础药物、专科药物及品牌医疗保健品研发、生产、市场推广及销售的领先企业─雅各臣科研制药有限公司(「雅各臣」或「公司」;股份代号:2633 )今天公布公司及其附属公司(统称「集团」)于截至二零二一年三月三十一日止年度(「二零二一财年」或「报告期」)的全年业绩。 more info >> |
|
雅各臣公佈二零二一財年全年業績 |
從事基礎藥物、專科藥物及品牌醫療保健品研發、生產、市場推廣及銷售的領先企業─雅各臣科研製藥有限公司(「雅各臣」或「公司」;股份代號:2633 )今天公佈公司及其附屬公司(統稱「集團」)於截至二零二一年三月三十一日止年度(「二零二一財年」或「報告期」)的全年業績。 more info >> |
|
Jacobson Pharma Announces FY2021 Annual Results |
Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaging in the research, development, production, marketing and sale of essential medicines, specialty drugs and branded healthcare products more info >> |
|
Friday, February 5, 2021 |
|
健倍苗苗(保健)有限公司於香港聯交所主板掛牌上市 |
健倍苗苗(保健)有限公司 (「健倍苗苗」 或「公司」,連同其附屬公司統稱「集團」),一家總部設於香港的領先品牌醫療保健品推廣及分銷公司,業務遍及大中華、東南亞及其他選定國家,今天於香港聯合交易所有限公司(「香港聯交所」)主板正式掛牌買賣,股份代號為2161。 more info >> |
|
JBM (Healthcare) Limited Debuts on The Main Board of SEHK |
JBM (Healthcare) Limited ("JBM Healthcare" or "Company", together with its subsidiaries, the "Group"), a Hong Kong-based company that markets and distributes branded healthcare products across Greater China, Southeast Asia and certain other countries, started trading today on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK") under stock code 2161. more info >> |
|
Monday, January 25, 2021 |
|
健倍苗苗(保健)有限公司将从雅各臣科研制药有限公司分拆 |
健倍苗苗(保健)有限公司(「健倍苗苗」 或「公司」,连同其附属公司统称「集团」),一家总部设于香港的领先品牌医疗保健品推广及分销公司,产品据点遍及大中华、东南亚及其他选定国家,今天公布其股份于香港联合交易所有限公司(「香港联交所」)主板上市计划详情。 more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
王朝酒业公布2023年全年业绩
Mar 28, 2024 17:45 HKT/SGT
|
|
|
王朝酒業公佈2023年全年業績
Mar 28, 2024 17:42 HKT/SGT
|
|
|
Dynasty Fine Wines Announces 2023 Annual Results
Mar 28, 2024 17:35 HKT/SGT
|
|
|
东软教育:内生高质量发展 数字化赋能打开长远增长空间
Mar 28, 2024 16:45 HKT/SGT
|
|
|
東軟教育:內生高質量發展 數字化賦能打開長遠增長空間
Mar 28, 2024 16:42 HKT/SGT
|
|
|
Fosun's Next Step: "Deep Mining" for Stable Profits
Mar 28, 2024 16:26: JST
|
|
|
Mitsubishi Shipbuilding Receives Order from the University of Tokyo for "MiPoLin" Power Prediction and Lines Selection System
Mar 28, 2024 16:45 JST
|
|
|
浙江沪杭甬:业绩稳健向好 积极回馈股东 分红总额增长17.7%
Mar 28, 2024 15:43 HKT/SGT
|
|
|
Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 Study
Mar 28, 2024 15:42: JST
|
|
|
浙江滬杭甬:業績穩健向好 積極回饋股東 分紅總額增長17.7%
Mar 28, 2024 15:37 HKT/SGT
|
|
|
2023年收入、利潤實現「雙增長」 復星下一步:「深挖礦」,穩盈利
Mar 28, 2024 15:31 HKT/SGT
|
|
|
Fosun's Next Step: "Deep Mining" for Stable Profits
Mar 28, 2024 15:26 HKT/SGT
|
|
|
Turning Loss into Profit in 2023: IGG Achieved over HK$430 million in 2H23
Mar 28, 2024 15:25: JST
|
|
|
国际债券持有人特别团体(“持有人特别团体”)指示受托人 向香港上市公司希教国际控股(1765.HK)送达清盘呈请书
Mar 28, 2024 15:21 HKT/SGT
|
|
|
Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 Study
Mar 28, 2024 14:42 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|